Insights

Gathering insights about Silo…

Similar companies to Silo

Silo Tech Stack

Silo uses 8 technology products and services including Hotjar, GitHub, Atlassian Jira, and more. Explore Silo's tech stack below.

Hotjar
Analytics
GitHub
Communication And Collaboration
Atlassian Jira
Issue Trackers
Mapbox GL JS
Maps
Microsoft Azure
Platform As A Service
reCAPTCHA
Security
Google Tag Manager
Tag Management
Appcues
User Onboarding

Media & News

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia
Key preclinical milestone for novel, non-opioid extended-release pain therapeutic SARASOTA, FL, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the initiation of a pharmacokinetic (PK) and tolerability study in partnership with its contract research organization (CRO), AmplifyBio. The study is designed to assess the pharmacokinetics of Silo's dissolvable ketamine-based injectable implant, SP-26, in a minipig model.
Dec 18, 2024 | www.globenewswire.com
Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management
Prototype development and feasibility testing underway for optimized subcutaneous delivery SARASOTA, FL, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced a collaboration agreement with Kymanox for specialized design and development of a subcutaneous insertion device for SP-26, the Company's ketamine-loaded implant therapeutic targeting fibromyalgia and chronic pain. Under terms of the agreement, Kymanox will conduct an initial proof-of-concept design phase followed by full system prototype and feasibility testing to determine optimal insertion depth in tissue.
Nov 29, 2024 | www.globenewswire.com
Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical study for managing severe conditions
Nov 18, 2024 | www.globenewswire.com
Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant
The implant demonstrates stability and consistent drug release, supporting further analytical testing and development SARASOTA, FL, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced promising results from recent sterilization and dissolution tests of its SP-26 ketamine-loaded implant for fibromyalgia and chronic pain. These tests were conducted under the Company's current development agreement with Sever Pharma Solutions.
Oct 31, 2024 | www.globenewswire.com
Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD
Proposal submitted for FDA 505(b)(2) regulatory pathway for SPC-15 approval Advancing path to IND submission for first-in-human trials SARASOTA, FL, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the completion of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) regarding the Company's development plan for SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD) and stress-induced anxiety disorder.
Sep 10, 2024 | www.globenewswire.com
Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
SP-26 dissolvable ketamine-based injectable implant targets chronic pain and fibromyalgia Sever Pharma to scale-up extrusion processes and continue analytical testing for novel non-opioid treatment SARASOTA, FL, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced a new agreement with Sever Pharma Solutions for scale-up extrusion of the Company's SP-26 ketamine-loaded implant therapeutic targeting fibromyalgia and chronic pain. In addition, Sever Pharma Solutions will continue with analytical testing of the ketamine hydrochloride (ketamine HCL) polymer implants using the optimal time-released, dose-controlled formulation previously selected by Silo for continuing pre-clinical studies.
Aug 14, 2024 | www.globenewswire.com
Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide
Silo to advance homing peptide development for initial indication in multiple sclerosis SARASOTA, FL, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into an agreement with WuXi AppTec (Hong Kong) Limited, a leading global contract research organization (CRO), for a preclinical small animal study of SPU-16, a central nervous system (CNS) homing peptide targeting multiple sclerosis (MS). Silo Pharma is advancing the development of the SPU-16 liposomal homing peptide through a commercial evaluation license and option agreement with the University of Maryland, Baltimore (UMB).
Aug 07, 2024 | www.globenewswire.com

Silo's Email Address Formats

Silo uses at least 1 format(s):

Silo Email Formats	Example	Percentage
First@usesilo.com	John@usesilo.com	37%
Last@usesilo.com	Doe@usesilo.com	13%
First@usesilo.com	John@usesilo.com	37%
Last@usesilo.com	Doe@usesilo.com	13%

Frequently Asked Questions

Where is Silo's headquarters located?

Silo's main headquarters is located at San Francisco San Francisco, CA 94111 US. The company has employees across 6 continents, including North AmericaEuropeAsia.

What is Silo's stock symbol?

Silo is a publicly traded company; the company's stock symbol is SILO.

What is Silo's official website and social media links?

Silo's official website is usesilo.com and has social profiles on LinkedIn.

How much revenue does Silo generate?

As of November 2024, Silo's annual revenue reached $15M.

What is Silo's NAICS code?

Silo's NAICS code is 5112 - Software Publishers.

How many employees does Silo have currently?

As of November 2024, Silo has approximately 154 employees across 6 continents, including North AmericaEuropeAsia. Key team members include Head Of Payments: C. B.Head Of Finance And Accounting: B. O.Head Of People And Culture: C. G.. Explore Silo's employee directory with LeadIQ.

What industry does Silo belong to?

Silo operates in the Software Development industry.

What technology does Silo use?

Silo's tech stack includes HotjarGitHubAtlassian JiraMapbox GL JSMicrosoft AzurereCAPTCHAGoogle Tag ManagerAppcues.

What is Silo's email format?

Silo's email format typically follows the pattern of . Find more Silo email formats with LeadIQ.

How much funding has Silo raised to date?

As of November 2024, Silo has raised $35M in funding. The last funding round occurred on Jul 12, 2023 for $35M.

When was Silo founded?

Silo was founded in 2018.

Silo

Software DevelopmentCalifornia, United States51-200 Employees

INTEGRATED SOFTWARE AND FINANCING SOLUTIONS FOR THE FOOD SUPPLY CHAIN											
Stay fresh. Stay ahead.											
Advance your business with Silo’s integrated software solutions and financing services. Silo Capital services, including Instant Pay and Cash Advance, are strategically designed to boost cash flow and support growth. Additionally, our software solutions—covering inventory, orders, payments, and logistics—streamline operations for more effective management of perishable goods in a competitive market.

Company Overview

Headquarters: San Francisco San Francisco, CA 94111 US
Website: usesilo.com
Stock Symbol: SILO
NAICS Code: 5112 - Software Publishers
Founded: 2018
Employees: 51-200

Media & News

Funding & Financials

$35M
Silo has raised a total of $35M of funding over 7 rounds. Their latest funding round was raised on Jul 12, 2023 in the amount of $35M.
$10M$50M
Silo's revenue is in the range of $10M$50M

Funding & Financials

$35M
Silo has raised a total of $35M of funding over 7 rounds. Their latest funding round was raised on Jul 12, 2023 in the amount of $35M.
$10M$50M
Silo's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Silo

Conservis

AgriWebb

Agworld

Granular

Cropio

Cultura Technologies

Silo Tech Stack

Media & News

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

Silo's Email Address Formats

Frequently Asked Questions

Where is Silo's headquarters located?

What is Silo's stock symbol?

What is Silo's official website and social media links?

How much revenue does Silo generate?

What is Silo's NAICS code?

How many employees does Silo have currently?

What industry does Silo belong to?

What technology does Silo use?

What is Silo's email format?

How much funding has Silo raised to date?

When was Silo founded?

Silo

Company Overview

Media & News

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?